Why and how antipsychotic drugs are used in 40 Sydney nursing homes

For decades there has been a high use of antipsychotic medication in nursing homes, though recently the use of typical antipsychotics has reduced while use of atypical antipsychotic medication has increased. The Australian government subsidises use of the latter in management of schizophrenia, and since April 2005 has subsidised use of risperidone (but still not the other atypicals) in cases of dementia with behavioural disturbance. This study was designed to examine the pattern of, and reasons for, antipsychotic use in a range of Sydney nursing homes.

[1]  S. Ellenberg.  Food and Drug Administration (FDA) , 2005 .

[2]  David Taylor,et al.  Testing for diabetes in hospitalised patients prescribed antipsychotic drugs , 2004, British Journal of Psychiatry.

[3]  S. Abidi,et al.  From Chlorpromazine to Clozapine—Antipsychotic Adverse Effects and the Clinician's Dilemma , 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[4]  P. Rochon,et al.  Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults , 2003, Pharmacotherapy.

[5]  J. Morley.  Hormones and the Aging Process , 2003, Journal of the American Geriatrics Society.

[6]  H. Brodaty,et al.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. , 2003, The Journal of clinical psychiatry.

[7]  J. Caro,et al.  The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. , 2002, The Journal of clinical psychiatry.

[8]  Julie Kreyenbuhl,et al.  Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study , 2002, BMJ : British Medical Journal.

[9]  G. Christodoulou,et al.  Medico-legal implications of drug treatment in dementia: prescribing out of licence , 2002 .

[10]  Jonathan M. Meyer.  A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.

[11]  Robert Rosenheck,et al.  Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. , 2002, The American journal of psychiatry.

[12]  A. Burns,et al.  Guidelines for the management of agitation in dementia , 2001, International journal of geriatric psychiatry.

[13]  A. Sinclair,et al.  Prevalence of diabetes in care home residents. , 2001, Diabetes care.

[14]  S. Tunis,et al.  Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[15]  D. Taylor,et al.  Atypical antipsychotics and hyperglycaemia , 2001, International clinical psychopharmacology.

[16]  J. Mintzer.  Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. , 2001, The Journal of clinical psychiatry.

[17]  W. Wirshing.  Movement disorders associated with neuroleptic treatment. , 2001, The Journal of clinical psychiatry.

[18]  D. Wirshing.  Adverse effects of atypical antipsychotics. , 2001, The Journal of clinical psychiatry.

[19]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[20]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[21]  J. Snowdon.  A follow‐up survey of psychotropic drug use in Sydney nursing homes , 1999, The Medical journal of Australia.

[22]  P. Tariot,et al.  Diabetes and Dementia in Long‐Term Care , 1999, Journal of the American Geriatrics Society.

[23]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[24]  H. Sackeim,et al.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. , 1998, The American journal of psychiatry.

[25]  T. Einarson,et al.  Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. , 1998, The Journal of clinical psychiatry.

[26]  L. Schneider,et al.  A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia , 1990, Journal of the American Geriatrics Society.

[27]  P. Mandelstam.  Hormones and the Aging Process , 1957, The Yale Journal of Biology and Medicine.

[28]  P. Haddad,et al.  Adverse Effects of Atypical Antipsychotics , 2007, CNS drugs.

[29]  N. Herrmann,et al.  Do Atypical Antipsychotics Cause Stroke? , 2005, CNS drugs.

[30]  G. Alexopoulos,et al.  Using antipsychotic agents in older patients. , 2004, The Journal of clinical psychiatry.

[31]  L. Dixon,et al.  Prevalence and correlates of diabetes in national schizophrenia samples. , 2000, Schizophrenia bulletin.

[32]  C. Doyle,et al.  Care Needs of People with Dementia and Challenging Behaviour Living in Residential Facilities - Summary Report 1996 , 1997 .